KEYNOTE-585

NCT03221426 📎

Regimen

Experimental
neoadjuvant + adjuvant pembrolizumab + chemotherapy (cisplatin/fluoropyrimidine or FLOT)
Control
placebo + chemotherapy (cisplatin/fluoropyrimidine or FLOT)

Population

Treatment-naive locally advanced resectable gastric/GEJ cancer

Key finding

Main cohort: mOS 71.8 vs 55.7 mo (HR 0.86, 95% CI 0.71-1.06, NS); EFS HR 0.81 (95% CI 0.67-0.98); pathCR improved

Source: PMID 40829093

Timeline

    Guideline citations

    • NCCN GASTRIC (p.126)
    • CSCO GASTRIC 2025 (p.67)⚠️ OCR source